$COCP

Cocrystal Pharma, Inc. (COCP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001412486 0001412486 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

Original reporting
Published Jun 9, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$COCP
Neutral
medium confidence
Mentioned
$COCP
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$COCPNeutralLow
01

Why it matters

The disclosure provides concrete incentive structure (salary, bonus, option strike at $1.05, and acceleration triggers) that may influence expectations for execution and potential M&A/strategic actions, but it does not provide new operating metrics.

02

Market read

Traders may reassess COCP’s governance/execution outlook due to the CEO transition, but the filing lacks pipeline or financial catalysts.

03

What to watch

Investors may focus on whether the incoming CEO’s prior GI-focused background translates to Cocrystal’s current development priorities, but the filing does not specify strategy changes.

Relevance 6/10Novelty 6/10Timing: effective immediately (CEO appointment dated June 3, 2026; filed June 9, 2026)

Background

The 8-K (Item 5.02) reports a CEO appointment and related compensatory arrangements, replacing the company’s co-CEOs.

Company-level read

Ticker impact

$COCPNeutralMedium confidence
Context

Cocrystal Pharma appointed James Sapirstein as CEO and disclosed his base salary, bonus, and 10-year option grants with vesting/acceleration terms.

Expected impact

Likely modest, sentiment-neutral reaction unless investors view the CEO change as a clear strategic inflection.

Evidence & confidence

The filing is a primary disclosure (8-K Item 5.02) but it does not include clinical/product updates or financial guidance; impact is mainly governance/expectations rather than fundamentals.

Market effects

Biopharma governance changes can affect perceived pipeline execution quality, but no sector-wide regulatory/clinical catalyst is disclosed here.

No specific regional market linkage beyond US-listed small-cap biotech sentiment.

No direct global operational or partnership update is provided.

Counterpoint

Equity compensation and vesting acceleration are standard; without pipeline/clinical milestones, the market may discount the CEO change as non-informative.

Key entities

  • Cocrystal Pharma, Inc.

    Nasdaq-listed biopharmaceutical company filing the 8-K regarding CEO appointment and compensation.

  • James Sapirstein

    Appointed Chief Executive Officer effective immediately; receives base salary, performance bonus, and option grants with vesting/acceleration terms.

  • Sam Lee

    Former co-CEO; continues as President and Chief Scientific Officer.

  • James Martin

    Former co-CEO; continues as Chief Financial Officer and signs the filing.

Related articles

$SKHYMed

SK Hynix’s $38 billion buildout has a name attached: Nvidia

SK Hynix (SKHY) approved about 54.3 trillion won (about $38.3B) for two memory plants through 2031, Reuters reported. About 35.2 trillion won funds a DRAM fab in Yongin (Y2) with construction starting July 2027 and first cleanroom June 2029. Remaining 19.1 trillion won supports a NAND plant in Cheongju. Reuters also said it is reviewing further shareholder returns.

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

$MTZMed

Is MasTec’s Debt Raise and Upgraded Guidance Altering The Investment Case For MasTec (MTZ)?

MasTec (MTZ) completed a $647.76 million fixed-rate senior unsecured notes offering with a 5.85% coupon due Sept. 30, 2036. The company reported Q2 2026 sales of $4,373.55 million and net income of $130.12 million, and raised full-year 2026 revenue guidance to $18.2 billion and GAAP net income to $539 million, citing balance-sheet flexibility and governance updates.